@FiercePharma: UPDATED: Valeant, Shire prep Salix bids. Article | Follow @FiercePharma
@CarlyHFierce: ICYMI yesterday: Teva 'likely' violated FCPA, local laws in Russia, Latin America and elsewhere. Report | Follow @CarlyHFierce
> Shire ($SHPG) says its $1.6 billion deal breakup fee from AbbVie ($ABBV) is tax-free. Report
> Boehringer Ingelheim and Sanofi ($SNY) have both acknowledged violating the U.K.'s APBI marketing code. Report
> Actavis ($ACT) is divesting Pharmatech, a pharmaceutical outsourcing and R&D business within subsidiary Aptalis, to global investment firm TPG. Release
> Merck KGaA will take full promotional responsibility for Erbitux in Japan with the end of a copromotion pact with Bristol-Myers Squibb ($BMY). Report
> Alaska's attorney general is pulling Impax Laboratories ($IPXL) into its investigation of pay-to-delay deals around three brand-name drugs. Report
> Both Indian and Western drugmakers are reportedly interested in buying the sterile injectable business of India's Claris Lifesciences. Report
Medical Device News
@FierceMedDev: J&J joins forces with JDRF for type 1 diabetes Dx. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: NIH discusses 'precision medicine' genomics initiative and how to build a million-person research cohort. Item | Follow @VarunSaxena2
@EmilyWFierce: Better training for pediatricians could help increase use of IUDs in teenage girls. Story from The Atlantic | Follow @EmilyWFierce
> USAID backs wearable tech initiative for Ebola from Scripps. Article
> Disposable insulin device maker Valeritas files to raise up to $90M in an IPO. Report
Biotech News
@FierceBiotech: Eisai wins an early FDA nod for its self-described cancer blockbuster. Report | Follow @FierceBiotech
@JohnCFierce: Biotech boom drives blockbuster VC investments in Boston, San Francisco. Story | Follow @JohnCFierce
@DamianFierce: Eisai exec told WSJ yesterday that lenvatinib approval was "imminent." Well. FDA announcement | Follow @DamianFierce
> The curious case of Xoma.com. Item
> Activists want Ariad's CEO out the door, report says. More
> Shire and Valeant are reportedly eyeing $10B bids for Salix. Report
And Finally... Vitamin D deficiency in childhood may be linked to heart risks in middle age, a study has found. More